AIS holding, part of the Rostec State Corporation, has acquired 25% of OneCell shares. It develops medical software based on AI for the diagnosis of oncological diseases.
OneCell is engaged in digital analysis of patient biomaterials. In real time, specialized software can process about 20,000 microphotographs per minute. This increases the speed and accuracy of diagnosis. AI-powered tools help in choosing the optimal treatment.
The solutions developed by our partners from OneCell represent a real revolution in the diagnosis of cancer. They have already passed clinical trials, confirmed their effectiveness and are actively developing in Moscow with the support of the Department of Health.
According to him, the demand for these technologies is high. Chemezov is confident that such developments need to be scaled up in the regions of Russia. He said that in the future, OneCell technology could be used to create a national digital diagnostic circuit as part of a federal project to digitalize pathological anatomy.
The press service of Rostec is confident that cooperation between Rostec and OneCell will raise the diagnosis of oncological diseases to a new level. The use of digital solutions will help both patients and doctors.
Read more on the topic:
Rostec launched the production of medical ultrasound equipment
Rosatom is testing generators for the production of radiopharmaceuticals
Rostec has developed and successfully tested a complex for minimally invasive surgical operations
